Cambridge Heart Appoints New Vice President; Robert LaRoche Hired to Lead Sales and Marketing.

Business Editors/Health/Medical Writers

BEDFORD, Mass.--(BUSINESS WIRE)--April 22, 2003

Cambridge Heart, Inc. (NASDAQ-CAMH) announced today that it has hired Mr. Robert LaRoche as its Vice President of Sales and Marketing. Mr. LaRoche spent 10 years at C.R. Bard where he started as a sales representative in the New England territory. He was Sales Representative of the Year for two consecutive years at Bard Interventional Products and then started his ascent through the marketing ranks of two different divisions of Bard, including their Gastroenterology and Cardiology Divisions.

He gained small company experience at Vision Sciences, Inc. where he was Vice President of Sales and Marketing and became intimately involved with the efforts to gain reimbursement for Vision Sciences' innovative flexible endoscope sheath product.

For the past few years Mr. LaRoche has been President of his own consulting company, Octant Marketing, Inc. where he was key in assisting small companies in sorting out their distribution issues, product positioning, sales staffing and strategic planning.

Commenting on the addition of Mr. LaRoche to his staff, David A. Chazanovitz, President and CEO of Cambridge Heart. made the following comments. "I am enormously pleased that Bob has decided to join Cambridge Heart. I have known him for more than fifteen years and know that he will instill in our organization the same tenacity that he has developed over his business career. His consulting experience makes him an expert at asking questions and this skill will enable us to better position Microvolt T-Wave Alternans, making us more effective with our customers. The take charge attitude, coupled with enthusiasm and drive will add additional accountability and be key in fulfilling our expectations."

Mr. Eric Dufford, former Vice President of Sales and Marketing has left the Company to pursue other interests.

About the Cambridge Heart Microvolt T-Wave Alternans Test

The Cambridge Heart Microvolt T-Wave Alternans Test measures extremely subtle beat-to-beat fluctuations in a person's heartbeat called T-wave alternans. These tiny heartbeat variations - measured at one millionth of a volt - are detected in any clinical setting where titration of the heart rate is possible. The preparation for the test consists of placing proprietary sensors on a patient's chest. Extensive clinical research has shown that patients with symptoms of or at risk of life threatening arrhythmias who test positive for T-wave alternans are at significant risk for subsequent sudden cardiac events including sudden death, while those who test negative are at minimal risk.

About Cambridge Heart

Cambridge Heart is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. Using innovative technologies, the company is addressing such key problems in cardiac diagnosis as the identification of those at risk of sudden cardiac arrest. The Company's products incorporate its proprietary technology, Microvolt T-Wave Alternans, and are the only diagnostic tools cleared by the U.S. Food and Drug Administration to non-invasively measure microvolt levels of T-wave alternans. The Company, founded in 1990, is based in Bedford, Massachusetts and is traded on the NASDAQ/SmallCap under the symbol CAMH. Cambridge Heart can be found on the World Wide Web at www.cambridgeheart.com.

Statements contained in this press release about anticipated revenue growth, and all other statements that are not purely historical, are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. In some cases, we use words such as "believes", "expects", "anticipates", "plans", "estimates" and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements. Factors that may cause or contribute to such differences include failure to obtain funding necessary to develop or enhance our technology, adverse results in future clinical studies of our technology, failure to obtain or maintain patent protection for our technology, failure to obtain or maintain adequate levels of third-party reimbursement for use of our products and other factors identified in our most recent Quarterly Report on Form 10-Q under "Factors Which May Affect Future Results", which is on file with the SEC. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.